- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 2, 2024
Discovery & Translation
Science spotlight: Doudna lab’s cell-penetrating CRISPR RNPs, durable epigenome editing and more
BioCentury’s roundup of translational innovations
BioCentury | Mar 7, 2020
Product Development
If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation
NoNO could deliver the first approval for stroke in 25 years, if it can avoid interactions with tPA SOC.
BioCentury | Jan 20, 2014
Emerging Company Profile
Zocere: Stepping up in stroke
Zocere aims to decrease ischemic stroke damage with STEP-based peptides
BioCentury | Apr 29, 2013
Emerging Company Profile
Avilex: One-two pain punch
Avilex's dimeric inhibitor shows greater potency for pain target PSD95
Items per page:
1 - 10 of 13